2. Search Result
Search Result
Results for "

3',5'-cyclic monophosphate

" in MedChemExpress (MCE) Product Catalog:

51

Inhibitors & Agonists

2

Biochemical Assay Reagents

1

Peptides

17

Natural
Products

7

Isotope-Labeled Compounds

3

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B1511
    Cyclic AMP
    Maximum Cited Publications
    11 Publications Verification

    cyclic adenosine monophosphate; Adenosine cyclic 3', 5'-monophosphate; cAMP

    		 Endogenous Metabolite Neurological Disease Metabolic Disease Cancer
    Cyclic AMP (Cyclic adenosine monophosphate), adenosine triphosphate derivative, is an intracellular signaling molecule responsible for directing cellular responses to extracellular signals. Cyclic AMP is an important second messenger in many biological processes .
    Cyclic AMP
  • HY-B1511A
    Cyclic AMP sodium
    Maximum Cited Publications
    11 Publications Verification

    cyclic adenosine monophosphate sodium; Adenosine cyclic 3', 5'-monophosphate sodium; cAMP sodium; cyclic AMP sodium

    		 Biochemical Assay Reagents Neurological Disease Metabolic Disease Cancer
    Cyclic AMP (Cyclic adenosine monophosphate) sodium, adenosine triphosphate derivative, is an intracellular signaling molecule responsible for directing cellular responses to extracellular signals. Cyclic AMP sodium is an important second messenger in many biological processes .
    Cyclic AMP sodium
  • HY-B1511R
    Cyclic AMP (Standard)

    cyclic adenosine monophosphate (Standard); Adenosine cyclic 3', 5'-monophosphate (Standard); cAMP (Standard)

    		 Endogenous Metabolite Cancer
    Cyclic AMP (Standard) is the analytical standard of Cyclic AMP. Cyclic AMP (Cyclic adenosine monophosphate), adenosine triphosphate derivative, is an intracellular signaling molecule responsible for directing cellular responses to extracellular signals. Cyclic AMP is an important second messenger in many biological processes .
    Cyclic AMP (Standard)
  • HY-108974
    Drotaverine hydrochloride

    		Phosphodiesterase (PDE) Calcium Channel Neurological Disease
    Drotaverine hydrochloride is a type 4 cyclic nucleotide phosphodiesterase (PDE4) inhibitor and an L-type voltage-dependent calcium channel (L-VDCC) blocker, blocks the degradation of 3',5'-cyclic adenosine monophosphate. Drotaverine (hydrochloride) exhibits in vivo antispasmodic efficacy without anticholinergic effects.
    Drotaverine hydrochloride
  • HY-131755
    2'-Deoxyadenosine 3':5'-cyclic monophosphate sodium

    		Biochemical Assay Reagents
    2'-Deoxyadenosine 3':5'-cyclic monophosphate (sodium) is a kind of biochemical reagent.
    2'-Deoxyadenosine 3':5'-cyclic monophosphate sodium
  • HY-N8209
    (+)-Medioresinol Di-O-β-D-glucopyranoside

    		Phosphodiesterase (PDE) Inflammation/Immunology
    (+)-Medioresinol Di-O-β-D-glucopyranoside is a lignan glucoside with strong inhibitory activity of 3', 5'-cyclic monophosphate (cyclic AMP) phosphodiesterase .
    (+)-Medioresinol Di-O-β-D-glucopyranoside
  • HY-153538
    AP-C2

    		Ser/Thr Protease Metabolic Disease
    AP-C2 is a potent guanosine 3',5'-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) inhibitor with a pIC50 of 5.2 .
    AP-C2
  • HY-131842
    6-Bn-cAMP

    N6-Benzyladenosine-3',5'-cyclic monophosphate

    		 PKA Cancer
    6-Bn-cAMP is a site-selective activator of cAMP-dependent protein kinase (PKA) which does not activate Epac. 6-Bn-cAMP increases hydrolytic stability against PDE, esterases, amidases and considerably higher membrane permeability compared to cAMP .
    6-Bn-cAMP
  • HY-134389
    6-Phe-cAMP

    N6-Phenyladenosine-3',5'-cyclic monophosphate

    		 PKA Cancer
    6-Phe-cAMP is a site-selective and highly membrane-permeant activator of protein kinase A (PKA), with a strong preference for site A of both isozymes. 6-Phe-cAMP can undergo phosphorothioate modification .
    6-Phe-cAMP
  • HY-153540
    AP-C4

    		PKG Others
    AP-C4 is an inhibitor of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) with a pIC50 of 5.2. AP-C3 does not inhibit cGKII-dependent anion secretion .
    AP-C4
  • HY-153541
    AP-C7

    		PKG Others
    AP-C7 is an inhibitor of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) with a pIC50 of 5.0. AP-C7 only weakly inhibits cGKII-dependent anion secretion .
    AP-C7
  • HY-14841
    Gisadenafil

    UK-369003

    		 Phosphodiesterase (PDE) Neurological Disease
    Gisadenafil (UK-369003) is a specific, orally active phosphodiesterase 5 (PDE5) inhibitor with an IC50 of 3.6 nM and prevents degradation of cyclic guanosine monophosphate (cGMP) .
    Gisadenafil
  • HY-B1511S
    Cyclic AMP-13C5

    cyclic adenosine monophosphate-13C5; Adenosine cyclic 3', 5'-monophosphate-13C5; cAMP-13C5

    		 Isotope-Labeled Compounds Others
    Cyclic AMP- 13C5 is a deuterated cyclic AMP.
    Cyclic AMP-13C5
  • HY-153537
    AP-C1

    		PKG Others
    AP-C1 is a potent inhibitor of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) with a pIC50 of 6.5. AP-C1 only weakly inhibits cGKII-dependent anion secretion .
    AP-C1
  • HY-108619
    Gisadenafil besylate

    UK 369003-26

    		 Phosphodiesterase (PDE) Neurological Disease
    Gisadenafil besylate (UK 369003-26) is a specific, orally active phosphodiesterase 5 (PDE5) inhibitor with an IC50 of 3.6 nM and prevents degradation of cyclic guanosine monophosphate (cGMP) .
    Gisadenafil besylate
  • HY-131766
    2'-O-Me-cAMP

    2'-O-Methyladenosine-3',5'-cyclic monophosphate

    		 Ras Others
    2'-O-Me-cAMP is an analogue of natural signal molecule cAMP and a selective stimulator of the exchange factors activated by cAMP (Epac) with low membrane permeability .
    2'-O-Me-cAMP
  • HY-176049
    Dasatinib derivative 1

    		Drug Derivative Neurological Disease
    Dasatinib derivative 1 (2e) effectively releases NO and increases the concentration of 3′,5′-cyclic guanosine monophosphate, as well as maintains senolytic activity. Dasatinib derivative 1 (2e) can be used in the research for chronic ocular hypertension (COHT) glaucoma .
    Dasatinib derivative 1
  • HY-153539
    AP-C3

    		PKG Others
    AP-C3 is a potent inhibitor of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) with a pIC50 of 6.3. AP-C3 only weakly inhibits cGKII-dependent anion secretion .
    AP-C3
  • HY-159857
    Gp(2′-5′)Ap sodium

    Gp(2′-5′)Ap(3′) sodium; 2'5'-GpAp sodium; Guanylyl-(2′→5′)-3′-adenylic acid sodium

    		 Others
    Gp(2′-5′)Ap sodium is a linear dinucleotide analog after hydrolysis of cyclic guanosine monophosphate- adenosine monophosphate (2’3’-cGAMP) by phosphodiesterases. Due to its linear conformation, 2’5’GpAp is intended to serve as a negative control for 2’3’-cGAMP in type I IFN induction assays.
    Gp(2′-5′)Ap sodium
  • HY-147946
    PDE1-IN-4

    		Phosphodiesterase (PDE) Calcium Channel Inflammation/Immunology
    PDE1-IN-4 (compound 2g) is a potent and selective PDE1 (phosphodiesterase-1) inhibitor, with IC50 values of 10, 145, and 354 nM for PDE1C, PDE1A, and PDE1B, respectively. PDE1-IN-4 inhibits myofibroblast differentiation of human lung fibroblasts induced by TGF-β1. PDE1-IN-4 shows anti-fibrosis effects through the regulation of cAMP (3′,5′-cyclic adenosine monophosphate) and cGMP (3′,5′-cyclic guanosine monophosphate). PDE1-IN-4 can be used for idiopathic pulmonary fibrosis (IPF) research .
    PDE1-IN-4
  • HY-108974S
    Drotaverine-d10 hydrochloride

    		Isotope-Labeled Compounds Phosphodiesterase (PDE) Calcium Channel Neurological Disease
    Drotaverine-d10 (hydrochloride) is the deuterium labeled Drotaverine hydrochloride. Drotaverine hydrochloride is a type 4 cyclic nucleotide phosphodiesterase (PDE4) inhibitor and an L-type voltage-dependent calcium channel (L-VDCC) blocker, blocks the degradation of 3',5'-cyclic adenosine monophosphate. Drotaverine hydrochloride exhibits in vivo antispasmodic efficacy without anticholinergic effects[1][2].
    Drotaverine-d10 hydrochloride
  • HY-131823
    5,6-DCl-cBIMP

    		Phosphodiesterase (PDE) Others
    5,6-DCl-cBIMP, a cyclic adenosine monophosphate analog, can act as an agonist of PDE2 and significantly enhance the cAMP and cGMP hydrolytic activities of PDE2 .
    5,6-DCl-cBIMP
  • HY-153542
    AP-C6

    		PKG Others
    AP-C6 is a potent inhibitor of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) with a pIC50 of 6.5. AP-C6 concentration-dependently inhibits human cGKII activity in vitro. AP-C6 potentiate cAMP signaling by PDE inhibition .
    AP-C6
  • HY-120241
    Reticulol

    K 251-1

    		 Phosphodiesterase (PDE) Cancer
    Reticulol (K 251-1) is an inhibitor of cyclic adenosine 3', 5'-monophosphate phosphodiesterase. Reticulol shows antitumor activity independent with cell cycle arrest or apoptosis. Reticulol inhibits cell growth of murine melanoma cells and human lung tumor cells. Reticulol protects its lung metastasis via the bloodstream by inhibiting the growth of B16F10 melanoma .
    Reticulol
  • HY-130530
    AP-C5

    		Biochemical Assay Reagents Metabolic Disease
    AP-C5 displays selective inhibition of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) with a pIC50 of 7.2, which can be used for the research of diarrheal disease . AP-C5 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    AP-C5
  • HY-105084
    Lubeluzole

    		Sodium Channel Neurological Disease
    Lubeluzole is a neuroprotective anti-ischemic compound. Lubeluzole, but not its (-)-R-isomer, protects against sensorimotor deficits provoked by photochemical stroke in rats. Lubeluzole inhibited glutamate-stimulated guanosine 3',5'-cyclic monophosphate production with an IC50 of 37 nM. Lubeluzole also has the potential for developing a novel class of antibacterial adjuvants endowed with spasmolytic activity .
    Lubeluzole
  • HY-N0126
    Xanthone
    1 Publications Verification

    		 Monoamine Oxidase Calcium Channel Cardiovascular Disease Neurological Disease
    Xanthone is a monoamine oxidase A (MAO-A) inhibitor with an IC50 of 0.84 µM. Xanthon inhibits Norepinephrine (HY-13715) and high-K +-induced vasoconstriction with IC50 values of 60.26 μM and 82.9 μM, respectively. Xanthon increases intracellular cyclic adenosine 3′,5′-monophosphate (cAMP) content and blocks Ca 2+ channels. Xanthone is the scaffold of several pharmacologically active compounds .
    Xanthone
  • HY-117186
    Bis-propargyl-PEG6

    		PROTAC Linkers Metabolic Disease
    Bis-propargyl-PEG6 is a PEG-based PROTAC linker used in the synthesis of PROTACs. Bis-propargyl-PEG6 can be used to synthesize the polymer linked multimers of guanosine-3', 5'-cyclic monophosphates . Bis-propargyl-PEG6 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Bis-propargyl-PEG6
  • HY-133190
    Bis-propargyl-PEG7

    		PROTAC Linkers Metabolic Disease
    Bis-propargyl-PEG7 is a PEG-based PROTAC linker used in the synthesis of PROTACs. Bis-propargyl-PEG7 can be used to synthesize the polymer linked multimers of guanosine-3', 5'-cyclic monophosphates . Bis-propargyl-PEG7 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Bis-propargyl-PEG7
  • HY-W654000
    Cyclic GMP-13C,15N2

    Guanosine 3',5'-cyclic-13C,15N2 monophosphate

    		 Isotope-Labeled Compounds STING Endogenous Metabolite Inflammation/Immunology
    Cyclic GMP- 13C, 15N2 is 13C and 15N labeled Cyclic GMP. Cyclic GMP (cGAMP) is an endogenous second messenger that triggers interferon production in response to cytoplasmic DNA. Cyclic GMP activates the stimulator of interferon genes (STING), activating a signaling cascade that leads to the production of type I interferons and other immune mediators .
    Cyclic GMP-13C,15N2
  • HY-117715
    CK-3197

    		Phosphodiesterase (PDE) Cardiovascular Disease
    CK-3197 is a weak inhibitor of Peak lll cyclic 3'5'-adenosine monophosphate phosphodiesterase (CAMP PDEl). CK-3197 has hemodynamic and myocardial energetic effects in vivo. CK-3197 is an imidazolone derivative used as a selective positive inotropic agent for congestive heart failure .
    CK-3197
  • HY-173360
    PDE10A-IN-5

    		Phosphodiesterase (PDE) Cardiovascular Disease
    PDE10A-IN-5 (Compound A30) is an inhibitor of phosphodiesterase 10A (PDE10A) with oral activity, and its IC50 value is 3.5 nM. PDE10A-IN-5 exerts the activity of inhibiting pulmonary vascular remodeling by inhibiting PDE10A and activating the cyclic adenosine monophosphate (cAMP)-associated signaling pathway, and can be used for research in the field of pulmonary arterial hypertension .
    PDE10A-IN-5
  • HY-N0126R
    Xanthone (Standard)
    1 Publications Verification

    		 Reference Standards Monoamine Oxidase Calcium Channel Cardiovascular Disease Neurological Disease
    Xanthone (Standard) is the analytical standard of Xanthone (HY-N0126). This product is intended for research and analytical applications. Xanthone is a monoamine oxidase A (MAO-A) inhibitor with an IC50 of 0.84 µM. Xanthon inhibits Norepinephrine (HY-13715) and high-K +-induced vasoconstriction with IC50 values of 60.26 μM and 82.9 μM, respectively. Xanthon increases intracellular cyclic adenosine 3′,5′-monophosphate (cAMP) content and blocks Ca 2+ channels. Xanthone is the scaffold of several pharmacologically active compounds .
    Xanthone (Standard)
  • HY-B0442S
    Vardenafil-d5

    		Phosphodiesterase (PDE) Endogenous Metabolite Endocrinology
    Vardenafil-d5 is deuterium labeled Vardenafil. Vardenafil is a selective, orally active, potent inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil shows selectivity over PDE1 (180 nM), PDE6 (11 nM), PDE2, PDE3, and PDE4 (>1000 nM). Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil can be used for the research of erectile dysfunction[1][2].
    Vardenafil-d5
  • HY-B0442C
    Vardenafil dihydrochloride

    		Endogenous Metabolite Phosphodiesterase (PDE) Metabolic Disease Inflammation/Immunology Endocrinology Cancer
    Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM respectively, while IC50s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - .
    Vardenafil dihydrochloride
  • HY-B0442
    Vardenafil
    2 Publications Verification

    		 Phosphodiesterase (PDE) Endogenous Metabolite Metabolic Disease Inflammation/Immunology Endocrinology Cancer
    Vardenafil is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes [1]-[6].
    Vardenafil
  • HY-B0442A
    Vardenafil hydrochloride
    2 Publications Verification

    		 Phosphodiesterase (PDE) Endogenous Metabolite Metabolic Disease Inflammation/Immunology Endocrinology Cancer
    Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes [1]-[6].
    Vardenafil hydrochloride
  • HY-B0442B
    Vardenafil hydrochloride trihydrate
    2 Publications Verification

    		 Endogenous Metabolite Phosphodiesterase (PDE) Metabolic Disease Inflammation/Immunology Endocrinology
    Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes [1]-[6].
    Vardenafil hydrochloride trihydrate
  • HY-B0442AS
    Vardenafil-d5 hydrochloride

    		Endogenous Metabolite Phosphodiesterase (PDE) Isotope-Labeled Compounds Metabolic Disease Inflammation/Immunology Endocrinology
    Vardenafil-d5 hydrochloride is deuterated labeled Vardenafil hydrochloride (HY-B0442A). Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes [1]-[6].
    Vardenafil-d5 hydrochloride
  • HY-105349
    T-0156

    		Phosphodiesterase (PDE) Neurological Disease
    T-0156 is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor. T-0156 specifically inhibits the hydrolysis of cyclic guanosine monophosphate (cGMP) by PDE5 in a competitive manner (IC50=0.23 nM). T-0156 inhibits PDE6 (IC50=56 nM) and has low potencies against PDE1, PDE2, PDE3, and PDE4 (IC50>10 μM). T-0156 enhances the nitric oxide (NO)/cGMP pathway .
    T-0156
  • HY-B0442CR
    Vardenafil (dihydrochloride) (Standard)

    		Endogenous Metabolite Phosphodiesterase (PDE) Metabolic Disease Inflammation/Immunology Endocrinology Cancer
    Vardenafil (dihydrochloride) (Standard) is the analytical standard of Vardenafil (dihydrochloride). This product is intended for research and analytical applications. Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM respectively, while IC50s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - .
    Vardenafil (dihydrochloride) (Standard)
  • HY-B0442R
    Vardenafil (Standard)

    		Phosphodiesterase (PDE) Endogenous Metabolite Metabolic Disease Inflammation/Immunology Endocrinology
    Vardenafil (Standard) is the analytical standard of Vardenafil. This product is intended for research and analytical applications. Vardenafil is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes [1]-[6].
    Vardenafil (Standard)
  • HY-W049735R
    N,N,O-Tridesmethylvenlafaxine (Standard)

    		Drug Metabolite Endogenous Metabolite Metabolic Disease
    Vardenafil (dihydrochloride) (Standard) is the analytical standard of Vardenafil (dihydrochloride). This product is intended for research and analytical applications. Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM respectively, while IC50s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - .
    N,N,O-Tridesmethylvenlafaxine (Standard)
  • HY-B0442BR
    Vardenafil hydrochloride trihydrate (Standard)

    		Endogenous Metabolite Phosphodiesterase (PDE) Metabolic Disease Inflammation/Immunology Endocrinology
    Vardenafil (hydrochloride trihydrate) (Standard) is the analytical standard of Vardenafil (hydrochloride trihydrate). This product is intended for research and analytical applications. Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes - .
    Vardenafil hydrochloride trihydrate (Standard)
  • HY-164685
    T-0156 free base

    		Phosphodiesterase (PDE) Neurological Disease
    T-0156 free base is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor. T-0156 free base specifically inhibits the hydrolysis of cyclic guanosine monophosphate (cGMP) by PDE5 in a competitive manner (IC50=0.23 nM). T-0156 free base inhibits PDE6 (IC50=56 nM) and has low potencies against PDE1, PDE2, PDE3, and PDE4 (IC50>10 μM). T-0156 free base enhances the nitric oxide (NO)/cGMP pathway .
    T-0156 free base
  • HY-18252
    Avanafil
    1 Publications Verification

    TA1790

    		 Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite Cardiovascular Disease Endocrinology
    Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .
    Avanafil
  • HY-18252R
    Avanafil (Standard)

    		Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite Cardiovascular Disease Endocrinology
    Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .
    Avanafil (Standard)
  • HY-18252A
    Avanafil dibenzenesulfonate

    TA1790 dibenzenesulfonate

    		 Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite Cardiovascular Disease Endocrinology
    Avanafil (TA-1790) dibenzenesulfonate is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil dibenzenesulfonate activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil dibenzenesulfonate inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil dibenzenesulfonate can be used for the research of erectile dysfunction and osteoporosis .
    Avanafil dibenzenesulfonate
  • HY-113972R
    Methyl mycophenolate (Standard)

    		Others Inflammation/Immunology
    Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .
    Methyl mycophenolate (Standard)
  • HY-18252S3
    Avanafil-13C5

    TA1790-13C5

    		 Isotope-Labeled Compounds Endogenous Metabolite Phosphodiesterase (PDE) NO Synthase Cardiovascular Disease Endocrinology
    Avanafil- 13C5 (TA1790- 13C5) is 13C labeled Avanafil. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .
    Avanafil-13C5

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: